Division of Johnson & Johnson
Latest From XO1 Ltd.
Index Ventures has spun off its life sciences team, portfolio companies and funds into a new venture capital firm called Medicxi Ventures, a validation of its "asset-centric" approach to investing.
J&J presented a far-reaching overview of its pharmaceutical portfolio and pipeline at an analyst day May 20, including plans to break into immuno-oncology, a strategy to develop a pan-genotypic HCV regimen and several filing timelines for new drugs.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced March 2015.
Janssen moves into a new generation of anticoagulation with X01 buyout. Lilly obtains Phase II-ready autoimmune candidate from South Korea’s Hanmi, which partnered a cancer compound with Spectrum just a week earlier, while AstraZeneca finds a commercialization partner for Movantik in Japan’s Daiichi Sankyo.
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Western Europe
- Parent & Subsidiaries
- Johnson & Johnson
- Senior Management
Richard Mason, CEO
David J Grainger, PhD, CSO
Robert W Schroff, PhD, COO
- Contact Info
Babraham Research Campus
Cambridge, CB22 3AT
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.